HALISTER: Amgen Boosts Forecast After 2Q Beats Estimates on Enbrel, Prolia

Amgen Boosts Forecast After 2Q Beats Estimates on Enbrel, Prolia

(Bloomberg) -- Amgen sees 2016 adj EPS $11.10-$11.40, saw $10.85-$11.20 (April 28), est. $11.17 (range $10.71-$12.23)
  • Sees 2016 rev. $22.5b-$22.8b, saw $22.2b-$22.6b, est. $22.57b (range $22.19b-$23.37b)
  • Still sees 2016 capex $700m
  • 2Q adj EPS $2.84, est. $2.74 (range $2.52-$2.94)
  • 2Q rev. $5.69b, est. $5.58b (range $5.34b-$5.75b)
    • Enbrel rev. $1.48b, est. $1.41b
    • Neulasta rev. $1.15b, est. $1.17b
    • Aranesp rev. $504m, est. $518.4m
    • Prolia rev. $441m, est. $389.1m
    • Xgeva rev. $381m, est. $381.0m
    • Sensipar/Mimpara rev. $389m, est. $380.9m
    • Epogen rev. $331m, est. $296.8m
    • Neupogen rev. $196m, est. $214.2m
    • Kyprolis rev. $172m, est. $182.1m
    • Blincyto rev. $30m, est. $28.4m
    • Repatha rev. $27m, est. $24.8m
  • Expects Repatha cardiovascular outcomes data in 1Q17, Kyprolis Phase 3 first-line multiple myeloma data in 2H16, erenumab (AMG 334) Phase 3 data in chronic migraine in 2H
  • Conf. call 5pm, 877-233-5736 pw 43870367; preview
Alert: HALISTER
Source: BFW (Bloomberg First Word)

Tickers
AMGN US (Amgen Inc)
AZN LN (AstraZeneca PLC)
4568 JP (Daiichi Sankyo Co Ltd)
GSK LN (GlaxoSmithKline PLC)
PFE US (Pfizer Inc)

To de-activate this alert, click here

UUID: 7947283